Search the Newsreel

Collegium Pharmaceutical, Inc. Stock 12‑Month Price Target Cut to $51.2, Implies 43% Upside

Collegium Pharmaceutical, Inc. (COLL) has seen its average 12-month price target reduced from $53.6 to $51.2 by 5 analysts, with individual forecasts ranging from $43 to $60. Despite this cut, the updated target still implies a significant 43% potential upside from its August 5 …

Collegium Pharmaceutical (COLL) Stock May Trade At A Discount Even After A 60% Return

Collegium Pharmaceutical (COLL) stock has seen a nearly 60% return over the past five years but may still be trading at a discount. Despite recent weakness, the company screens as undervalued in most measures, with its current P/E ratio of 12.6x being below the …

Colliers International Posts Revenue Growth and Stronger Earnings in Q2 2026 Filing

Colliers International Group (TSE:CIGI) reported significant revenue growth for Q2 2026, reaching $1.57 billion, and an increase in net earnings attributable to the company to $28.5 million. The company's Q2 filing detailed strong financial performance despite higher costs and non-controlling interests, with year-to-date revenues …

Colliers (CIGI) Drops 2.5% to $138.28 as Post-Earnings Drift Sets In

Collegium Pharmaceutical, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:COLL) 2026-08-07

Collegium Pharmaceutical, Inc. (COLL) released its Q2 2026 earnings call presentation. The company reported an EPS of $1.92, beating estimates by $0.16, and revenue of $199.88M, which missed estimates by $1.07M but represented a 6.32% year-over-year increase. This presentation provides details on their financial …

Collegium Pharmaceutical Inc (COLL) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Collegium Pharmaceutical Inc (COLL), detailing its current price momentum score, support and resistance levels, and indicator readings. It also covers moving average data and offers a technical summary, suggesting the stock is currently suitable for range-bound swing …

Grove Collaborative Holdings, Inc. 2026 Q2 - Results - Earnings Call Presentation (NYSE:GROV) 2026-08-07

Grove Collaborative (NYSE: GROV) posts smaller loss on lower revenue

Grove Collaborative Holdings, Inc. (NYSE: GROV) reported a smaller net loss of $0.9 million in Q2 2026, down from $3.6 million a year earlier, despite a decline in net revenue to $36.6 million from $44.0 million. The company's Adjusted EBITDA turned positive at $0.5 …

Collegium Pharmaceutical Releases Q2 2026 Financial Results

Collegium Pharmaceutical Inc. reported mixed Q2 2026 financial results, with adjusted earnings of $1.92 per share exceeding expectations, but revenue of $199.9M slightly missing estimates. The company's product, JORNAY PM, showed significant revenue growth of 41.0%, contributing to the positive outlook. Management issued full-year …

Office assets lead real estate investments across APAC and India in H1 2026, accounting for over 40% of total inflows in India: Colliers

APAC investments reach USD 105 billion in H1 2026, the strongest first half since 2022 Capital deployment in office assets across APAC markets touch USD 40.2 billion during H1 2026 Capital remains focused on most liquid markets such as Australia, China, Japan & Singapore …

CollPlant Biotechnologies Bolsters Authorized Share Capital and Validates Resale Shares After July Private Placement

Grove Collaborative Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

Grove's quarterly loss narrows to $0.9M as expenses fall 27%

Grove Collaborative Holdings, Inc. (NYSE: GROV) reported a narrowed net loss of $0.9 million in Q2 2026, down from $3.6 million in the prior year, as total operating expenses decreased by 27% to $20.4 million. The company achieved positive Adjusted EBITDA of $0.5 million …

Grove Collaborative Holdings, Inc. Reaffirms Earnings Guidance for Year Ending December 31, 2026

CollPlant Biotechnologies (CLGN) lifts share capital, files new resale opinion

CollPlant Biotechnologies (CLGN) reported that its shareholders approved an increase in authorized share capital from 30 million to 500 million ordinary shares, each with a par value of NIS 1.50. Following this approval, the company filed an updated legal opinion concerning the validity of …

Colliers International Group | 6-K: Report of foreign private issuer (related to financial reporting)

This article is a 6-K filing by Colliers International Group, which is a report of a foreign private issuer. These reports are submitted to the SEC by foreign companies to disclose material information. This specific filing is related to financial reporting.

Collegium Pharmaceutical (NASDAQ:COLL) Reports Sales Below Analyst Estimates In Q2 CY2026 Earnings, Stock Drops

Collegium Pharmaceutical falls 13% on weak revenue guidance

Collegium Pharmaceutical Inc. (NASDAQ:COLL) shares dropped 13.5% after reporting Q2 results that missed revenue expectations and issuing weaker-than-expected full-year guidance. Although adjusted EPS beat estimates, revenue fell short, and the company lowered its 2026 revenue and adjusted EBITDA forecasts. The decline was primarily attributed …

Collegium Pharmaceutical Reports Q2 2026 Results, Completes AZSTARYS Acquisition and Raises Full-Year Guidance

Collegium Reports Second Quarter 2026 Financial Results and Highlights Recent Company Progress

Collegium Pharmaceutical, Inc. reported strong Q2 2026 financial results, with net revenues up 6% year-over-year to $199.9 million, driven by a 41% increase in JORNAY PM revenue and the successful acquisition and initial sales of AZSTARYS. The company updated its full-year 2026 financial guidance, …

Collegium Pharmaceutical (COLL) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Colliers International Group (CIGI) lifts Q2 revenue 17% and expands engineering

Colliers International Group Inc. (CIGI) reported a 17% increase in Q2 2026 revenue, reaching $1.57 billion, driven by growth in Commercial Real Estate, Engineering, and Investment Management, with Engineering revenue alone growing 30% due to acquisitions like Ayesa Engineering. While net earnings decreased to …

Collegium Pharmaceutical (COLL): Principal Global Investors discloses 5% equity stake

Principal Global Investors has filed a Schedule 13G, reporting a passive 5% equity stake in Collegium Pharmaceutical, Inc. The firm beneficially owns 1,632,360 shares of common stock with shared voting and dispositive power. Both companies' principal offices are noted, with Collegium Pharmaceutical in Stoughton, …

Does Colliers (TSX:CIGI) Pairing Buybacks With Acquisition-Led Growth Clarify Its Long-Term Strategy?

Colliers International Group recently reported strong Q2 2026 results, showing increased sales and net income, and reaffirmed its full-year guidance for mid-teens revenue growth. The company plans to combine acquisition-led expansion with share buybacks in the second half of 2026, aiming to enhance per-share …

Collegium Pharmaceutical earnings ahead after ADHD acquisition

Collegium Pharmaceutical is set to report second-quarter earnings, with analysts anticipating increased revenue and earnings per share following the acquisition of ADHD medication AZSTARYS. Investors will closely watch the performance of AZSTARYS and the company's legacy pain medication portfolio, as well as updates on …

Stifel Maintains Colliers International Group(CIGI.US) With Buy Rating, Cuts Target Price to $155

Stifel has reiterated its Buy rating for Colliers International Group (CIGI.US) but has adjusted its target price downward to $155. This revision indicates a maintained positive outlook on the company's stock, despite a slight reduction in its valuation projection.

Earnings To Watch: Grove Collaborative Holdings Inc (GROV) Q2 2026 -- GF Value Sees 13% Downside

Top 8 ASX Consumer Services Stocks for August ’26: Collins Foods, Kelsian and Flight Centre Lead a Diverse Recovery Watchlist

Collegium Pharmaceutical (COLL) Reports Earnings Tomorrow: What To Expect

Dimensional Fund Advisors LP Boosts Stock Position in Colliers International Group Inc. $CIGI

Dimensional Fund Advisors LP increased its stake in Colliers International Group Inc. (NASDAQ:CIGI) by 15.1% in the first quarter, now owning 416,549 shares valued at $44.5 million. This comes as Colliers reported strong Q2 adjusted EPS of $1.83, exceeding estimates, though revenue fell short …

Coppa Collective plc (COPC.L) latest stock news and headlines

Collegium Pharma shifts focus to ADHD growth with AZSTARYS buy, expecting $865M revenue in 2026.

Collegium Pharmaceutical is transitioning into a central nervous system (CNS) platform company by acquiring the ADHD drug franchise AZSTARYS for $650 million. This strategic move is expected to generate $60–70 million in revenue by 2026 from AZSTARYS and create over $50 million in annual …

Colliers International Group Inc. Price Target Raised to $110.00/Share From $109.00 by National Bank

National Bank has increased its price target for Colliers International Group Inc. (CIGI) to $110.00 per share, up from $109.00. This adjustment reflects a positive outlook from the analyst at National Bank regarding the company's future performance. The stock is currently rated as "Outperform."

Public Employees Retirement System of Ohio Has $2.84 Million Stake in Colliers International Group Inc. $CIGI

The Public Employees Retirement System of Ohio has reduced its stake in Colliers International Group Inc. (CIGI) by 30.6% in the first quarter, now holding 26,670 shares valued at approximately $2.84 million. Despite this reduction, institutional investors collectively own 80.09% of CIGI, and analysts …

Colliers International on Track for Mid-Teen Earnings Growth, RBC Says

RBC Capital Markets has reiterated its Outperform rating and C$165 price target for Colliers International, citing expectations for mid-teen earnings growth. The firm's positive outlook is based on Colliers' diversified business model, strategic acquisitions, and robust capital allocation. RBC believes Colliers is well-positioned to …

Argent Capital Management LLC Buys 22,118 Shares of Colliers International Group Inc. $CIGI

Argent Capital Management LLC increased its holdings in Colliers International Group Inc. (NASDAQ:CIGI) by 51.6%, acquiring an additional 22,118 shares to reach a total of 64,980 shares valued at approximately $6.95 million. Despite a revenue miss, Colliers reported stronger-than-expected quarterly earnings per share of …